Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the international randomized study of interferon vs STI571 (IRIS)

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Author(s): Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Druker BJ, IRIS Study Grp

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Blood: 48th Annual Meeting of the American Society of Hematology

Year of Conference: 2006

Pages: 605A-606A no. 2136

ISSN: 0006-4971

Publisher: American Society of Hematology

URL: http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/2136

Library holdings: Search Newcastle University Library for this item

ISBN: 15280020

ePrints